周三盘中，脑再生科技（RGC）股价再度遭遇重挫，大跌8.15%。这一跌势延续了该股近期的下行趋势，引发市场对其短期走势的担忧。
数据显示，脑再生科技在过去5个交易日内累计下跌超过60%，显示出极高的波动性。尽管该股今年以来涨幅惊人，但近期的连续下跌或已触发了投资者的获利回吐。值得注意的是，该公司近期获得了FDA对其新一代神经调控芯片临床试验的审批，并宣布将与梅奥诊所合作研究帕金森病治疗，但这些利好消息似乎未能阻止股价下跌。
分析人士指出，脑再生科技作为一家专注于中医治疗神经认知障碍的早期生物科技公司，其股价的剧烈波动反映了市场对高成长性但高风险公司的态度转变。投资者需要密切关注公司后续的研发进展和财务状况，以评估其长期投资价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.